Oxanamide

Oxanamide
Clinical data
ATC code	none;
Identifiers
	IUPAC name 2-ethyl-3-propyloxirane-2-carboxamide;
CAS Number	126-93-2;
PubChem CID	31365;
ChemSpider	29098;
UNII	050271194T;
CompTox Dashboard (EPA)	DTXSID50925350 ;
Chemical and physical data
Formula	C8H15NO2
Molar mass	157.213 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC1C(O1)(CC)C(=O)N;
	InChI InChI=1S/C8H15NO2/c1-3-5-6-8(4-2,11-6)7(9)10/h6H,3-5H2,1-2H3,(H2,9,10); Key:WBLPIVIXQOFTPQ-UHFFFAOYSA-N;
	(verify)

Oxanamide (Quiactin) is an anxiolytic and muscle relaxant which can produce sedative and hypnotic effects in sufficiently high doses.^[1] An uncontrolled trial on patients treated in a clinical gynecology practice published in 1959 found that oxanamide was efficacious in the treatment of anxiety resulting from premenstrual syndrome, menopause, and various other causes, with minimal sedation or other side effects.^[2]

References[edit]

^ Kuhn WL, Ketteler HJ, Van Maanen EF (January 1960). "Effects of oxanamide on the central nervous system". Proceedings of the Society for Experimental Biology and Medicine. 103: 101–3. doi:10.3181/00379727-103-25425. PMID 14412594. S2CID 40927309.
^ Woodhull RB (April 1959). "Oxanamide; adjunctive use of a new tranquilizer in gynecology". California Medicine. 90 (4): 275–7. PMC 1577644. PMID 13638840.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

This sedative-related article is a stub. You can help Wikipedia by expanding it.

[1] Kuhn WL, Ketteler HJ, Van Maanen EF (January 1960). "Effects of oxanamide on the central nervous system". Proceedings of the Society for Experimental Biology and Medicine. 103: 101–3. doi:10.3181/00379727-103-25425. PMID 14412594. S2CID 40927309.

[2] Woodhull RB (April 1959). "Oxanamide; adjunctive use of a new tranquilizer in gynecology". California Medicine. 90 (4): 275–7. PMC 1577644. PMID 13638840.

[1]

[2]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III